About Sutter Hematology and Oncology
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Sutter Hematology and Oncology
During the past decade, Sutter Hematology and Oncology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
2010-04-01
2012-01-01
Completed
26
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
2011-09-01
2015-05-01
Completed
54
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
2014-02-20
2021-12-23
Completed
85
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
2016-09-09
2020-12-15
Completed
681
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
2017-03-24
2024-08-15
Active, not recruiting
1,239
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
2018-06-06
2023-02-17
Terminated
1,054
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
2020-11-26
2029-03-30
Recruiting
865
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Sutter Hematology and Oncology
According to Clinical.Site data, the most researched conditions in "Sutter Hematology and Oncology" are
"Lymphoma, Non-Hodgkin" (2 trials), "Lymphoma, B-Cell" (1 trials), "Lymphoma, Large B-Cell, Diffuse" (1 trials), "Lymphoma, Nonhodgkin" (1 trials) and "Neoplasms" (1 trials). Many other conditions were trialed in "Sutter Hematology and Oncology" in a lesser frequency.
Clinical Trials Intervention Types at Sutter Hematology and Oncology
Most popular intervention types in "Sutter Hematology and Oncology" are "Biological" (1 trials), "Drug" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.
The name of intervention was led by "Gene-modified (GM) T cell therapy" (1 trials), "Lenalidomide" (1 trials), "Rituximab" (1 trials) and "lisocabtagene maraleucel" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Sutter Hematology and Oncology
The vast majority of trials in "Sutter Hematology and Oncology" are
3 trials for "All" genders.
Clinical Trials Status at Sutter Hematology and Oncology
Currently, there are NaN active trials in "Sutter Hematology and Oncology".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 1 completed trials in Sutter Hematology and Oncology,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Sutter Hematology and Oncology, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".